400mcg Sublingual Misoprostol as First Line Treatment

Women presenting with incomplete abortion and eligible for treatment with misoprostol were offered 400mcg sublingual misoprostol for treatment. Based on existing literature, the study hypothesises that women can successfully be treated with misoprostol alone as first line treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Incomplete Abortion Abortion, Incomplete Abortion, Spontaneous Female Urogenital Diseases and Pregnancy Complications Pregnancy Complications Urogenital Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Guediawaye Health Center

Guédiawaye, Senegal

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

uterine size less than 12 weeks lmp
open cervical os
current or past vaginal bleeding
willing to provide contact information for follow-up
over 18 or with guardian consent

Exclusion criteria

suspicion of ectopic pregnancy
intrauterine device in place
bad general health (infection, anemia, shoc)

Treatment and study plan

Misoprostol

Drug

Primary outcomes

complete abortion

Time frame: 1 year

number of complete abortion with misoprostol treatment alone

Sponsors and collaborators

Lead sponsor

Gynuity Health Projects

Other

Registry information

Official study title

Introduction of 400mcg Sublingual Misoprostol as First Line Treatment in 11 Health Posts in Three Districts in Senegal

Important dates

Study start: 2011
Primary completion: 2012
Study completion: 2012
First posted: Sep 11, 2013
Registry last updated: Sep 11, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed